HCC testing that works for patients

See why the Oncoguard® Liver test is simple and convenient.

The Oncoguard® Liver test is a sophisticated, yet simple, single blood test delivering high sensitivity and specificity to aid consistent and reliable hepatocellular carcinoma (HCC) detection.

The convenience of accurate blood-based testing helps streamline HCC testing, making it easier for patients to follow through with their care.


A unique set of markers clarifies the information

The Oncoguard® Liver test analyzes plasma for methylated DNA markers (MDMs) and serum for the alpha-fetoprotein (AFP).

Methylated DNA markers are a class of biomarkers that may demonstrate aberrant methylation of gene promoter regions, which is common and widespread in HCC cells, even in early stages of the disease.1

High levels of AFP have been shown to be associated with liver diseases, including HCC,2 which is why AFP is the most widely used serological marker to help establish an HCC diagnosis.3

This unique combination of DNA and protein biomarkers employed in the Oncoguard® Liver test exhibits an additive association with HCC.


Sophisticated analysis
Actionable results

The Oncoguard® Liver test uses a sophisticated algorithm combining the patient’s biological sex with results from the analysis of AFP and the MDMs to generate an actionable qualitative result.


High result

A high test result may indicate the presence of HCC. When a positive result is reported, additional clinical assessment to confirm the presence of HCC is suggested (e.g., diagnostic imaging procedures).


Negative result

A negative test result indicates a lower likelihood of the presence of HCC. When a negative result is obtained, a 3- to 6-month surveillance cadence is suggested.

In rare instances, a technical failure or insufficient clinical material in the sample yields an invalid result.

False positive and false negative results are possible with the Oncoguard® Liver test. In the clinical lab validation study, the false positive rate was 13% and the false negative rate was 12%.4


By combining high sensitivity and specificity to detect HCC with easy-to-interpret qualitative results, the Oncoguard® Liver test may help you take action sooner and achieve the goal of better outcomes for your patients.

References: 1. Oussalah A, Rischer S, Bensenane M, et al. Plasma mSEPT9: a novel circulating cell-free DNA-based epigenetic biomarker to diagnose hepatocellular carcinoma. EBioMedicine. 2018;30:138-147. 2. Kew M. Alpha-fetoprotein in primary liver cancer and other diseases. Gut. 1974;15(10):814-821. 3. Bai D-S, Zhang C, Chen P, Jin S-J, Jiang G-Q. The prognostic correlation of AFP level at diagnosis with pathological grade, progression, and survival of patients with hepatocellular carcinoma. Sci Rep. 2017;7(1):12870. 4. Chalasani NP, Porter K, Bhattacharya A, Book AJ, Neis BM, Xiong KM, Ramasubramanian TS, Edwards V DK, Chen I, Johnson S, Roberts LR, Kisiel JB, Reddy KR, Singal AG, Olson MC, Bruinsma JJ, Validation of a novel multi-target blood test shows high sensitivity to detect early-stage hepatocellular carcinoma, Clinical Gastroenterology and Hepatology (2021),